Compare ABUS & CRAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABUS | CRAI |
|---|---|---|
| Founded | 2005 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2008 | 1998 |
| Metric | ABUS | CRAI |
|---|---|---|
| Price | $4.69 | $158.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $245.00 |
| AVG Volume (30 Days) | ★ 4.7M | 85.2K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.48% |
| EPS Growth | ★ 55.26 | 20.77 |
| EPS | 0.84 | ★ 8.14 |
| Revenue | $14,083,000.00 | ★ $751,583,000.00 |
| Revenue This Year | N/A | $7.82 |
| Revenue Next Year | $239.71 | $5.14 |
| P/E Ratio | ★ $5.71 | $20.23 |
| Revenue Growth | ★ 128.21 | 9.33 |
| 52 Week Low | $3.50 | $132.17 |
| 52 Week High | $5.45 | $227.29 |
| Indicator | ABUS | CRAI |
|---|---|---|
| Relative Strength Index (RSI) | 37.59 | 47.51 |
| Support Level | $4.42 | $152.37 |
| Resistance Level | $4.81 | $165.17 |
| Average True Range (ATR) | 0.09 | 5.17 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 16.48 | 58.47 |
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.